RxDoctor Payments DataLook up a doctor →

Matthew Budoff, MD

Cardiovascular Disease · Torrance, CANPI 1811967433

Payments from drug & device makers

$11,307,169in general payments, 2019–2025

Across 4,776 payments — averaging $2367.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1.9M
  • Novartis$1.5M
  • Amgen$1.3M
  • AstraZeneca$1.1M
  • GE HealthCare$673K
  • Novo Nordisk AS$546K
  • plus $4.3M from 53 others
$583,435in research payments, 2019–2025

Across 34 payments — averaging $17,160 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$526K
  • Novartis Pharma AG$19K
  • Novo Nordisk$18K
  • Canon Medical Informatics, Inc.$10K
  • Pfizer$4K
  • Amgen$3K
  • plus $3K from 2 others

What the payments were for

  • Consulting fees$424,82512%
  • Speaking & faculty fees$2,876,86680%
  • Grants$1,0000%
  • Travel & lodging$248,8747%
  • Food & beverage$62,9062%
  • Education$2,7180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk241$1,873,947
Novartis93$1,549,075
Amgen364$1,294,943
AstraZeneca473$1,082,584
GE HealthCare18$673,447
Novo Nordisk AS707$546,171
Boehringer Ingelheim International GmbH582$484,021
Lilly USA, LLC345$437,333
Boehringer Ingelheim181$408,738
Merck273$370,812
Boehringer Ingelheim Pharma GmbH & Co.kg61$344,010
Esperion Therapeutics, Inc.230$302,517
Amarin Pharma, Inc.230$299,055
Heartflow, Inc.144$248,361
Regeneron Healthcare Solutions, Inc.159$200,143
Pfizer121$188,633
Johnson & Johnson186$186,291
GE Global Research An Unincorporated Business Of GE Company2$157,252
Bayer83$136,548
Sanofi-aventis U.S. LLC78$105,338
Cleerly, Inc.19$96,732
Sanofi US Services Inc.17$65,249
Lexicon Pharmaceuticals, Inc.12$52,634
Ionis Pharmaceuticals, Inc.19$44,427
Seqirus USA Inc2$26,991
Eli Lilly14$25,257
Fukuda Denshi Co., Ltd.(2 entities)7$12,000
Corcept Therapeutics14$10,956
E.r. Squibb & Sons, L.L.C.10$7,327
AbbVie8$7,252
Astrazeneca UK Limited2$6,802
Kowa Pharmaceuticals America, Inc.6$6,583
Agepha Pharma FZ LLC3$6,524
Genentech, Inc.3$6,192
Renalytix AI, Inc.2$6,000
Abbott5$5,378
Elucid Bioimaging Inc2$5,283
Medicure Pharma Inc.2$4,500
Actelion Pharmaceuticals, Ltd6$4,361
Arineta, Inc1$4,355
Idorsia Pharmaceuticals US Inc1$3,540
Canon Medical Informatics, Inc.2$3,000
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)13$2,739
Boehringer Ingelheim Canada Ltd.ltee4$1,137
United Imaging Healthcare North America LLC1$812
Boehringer Ingelheim France S.a.s.4$798
Astellas Pharma US Inc5$255
Boston Scientific3$215
Medtronic2$187
Regeneron2$151
Actelion Pharmaceuticals US, Inc.5$98
Cook Medical LLC2$41
Akcea Therapeutics, Inc.1$36
Invivyd Inc1$31
Kiniksa Pharmaceuticals, Ltd.1$30
United Therapeutics Corporation1$23
Bridgebio Pharma, Inc.1$22
Alnylam Pharmaceuticals Inc.1$20
Teleflex LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,307,169 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$850,435
Medicare patients
1,752
Services billed
88,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab21$18,573
NexletolBempedoic Acid13$5,048
Rosuvastatin Calcium40$530
Atorvastatin Calcium22$263
Metoprolol Succinate19$139
Losartan Potassium18$111
Amlodipine Besylate12$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Esperion Therapeutics, Inc.Nexletol$302,517$5,04813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →